A new securities class action, filed Wednesday in Manhattan federal court, accused New York City-based health care logistics firm SCWorx Corp. of misleading investors about a supposed deal to buy and resell millions of COVID-19 rapid testing kits.
The lawsuit targeted SCWorx and its CEO Marc Schessel over an April 13 announcement that the company had secured a committed purchase order of two million test kits per week. The deal, SCWorx said at the time, included a provision for additional weekly orders of 2 million units over 23 weeks, valued at $35M per week.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]